The explosive new book, “Bottle of Lies: The Inside Story of the Generic Drug Boom,” was released today and, in response, top public health and policy experts are calling on the U.S. Congress and Food and Drug Administration (FDA) to hold hearings on generic drug safety in America. Specifically, and of great concern to the public health, is that a staggering 80% of the active ingredients in all of our nation’s drugs are manufactured overseas, primarily in India and China, where there is a proven track record of years of drastically poor regulation and accountability.
This impacts every American who takes generic medications – from grandparents to small children, from prescriptions for antibiotics and birth control pills and antidepressants to over-the-counter fever and pain medications and everything in-between, said a press note. Six years ago, drug supply chain expert Dinesh Thakur was a historic whistleblower who took on goliath pharmaceutical manufacturer Ranbaxy in India and won. The company paid $500 million to resolve criminal and civil allegations of falsified drug data and systemic manufacturing violations resulting in substandard and unapproved drugs sold in the U.S. market.
Fast forward to today and nothing has changed. The myth of U.S. generic drug safety continues to grow despite the realities outlined in the compelling book “Bottle of Lies,” where Thakur’s professional and personal battle to expose fraud in the generic drug industry is the bulk of the story. Thakur’s critical work now focuses on sharing what went wrong, providing implementable solutions and elevating the manufacturing standards of overseas facilities to those accepted by the FDA.
“The reality of the generic drug industry is that the U.S. Food and Drug Administration has done a good job of inspiring trust over the decades – leaving consumers to seldom question the quality of the nation’s drug supply,” said Dinesh Thakur, public health advocate and historic whistleblower. “The new book ‘Bottle of Lies’ exposes the truth – and it is critical that Congress hold hearings to address generic drug safety in America.”
“The current pass/fail system the U.S. has in place for generic manufacturers overseas is not working. We need either quality metrics for suppliers or more transparency to make quality-based purchasing decisions,” said Erin Fox, Senior Director of Drug Information and Support Services at University of Utah Health Care (UUHC). “Policymakers on Capitol Hill need to take the lead by working with the FDA to implement viable and permanent solutions to protect the nation’s generic drug supply and the health of consumers nationwide.”